KDR and neoplasm: Its binding to VEGFR2 blocks the interactions with its ligands, including VEGF-A, VEGF-C, and VEGF-D, thereby preventing VEGFR2 phosphorylation and downstream consequences such as proliferation, migration, and tube formation of human endothelial cells, finally inhibiting tumor angiogenesis.